Solvable models for the gamma deformation having X(5) as limiting symmetry. Removing some drawbacks of the existent descriptions

Two solvable Hamiltonians for describing the dynamic gamma deformation, are proposed. The limiting case of each of them is the X(5) Hamiltonian. Analytical solutions for both energies and wave functions, which are periodic in $\gamma$, are presented in terms of spheroidal and Mathieu functions, respectively. Moreover, the gamma depending factors of the transition operator can be treated.Comment: four two column pages, 1 figur

Occurrence and profiles of PCBs and PBDEs in harbour seals and harbour porpoises from the southern North Sea

Harbour porpoises (Phocoena phocoen) and harbour seals (Phoca vitulina), two representative top coastal pollution. Concentrations of sum PCBs were 1-2 orders of magnitude higher than concentrations of sum PBDEs (with median values of 23.1 μg.g- lw (lipid weight) and 12.4 μ.g-1 lw for sum PCBs and 0.33 μ.g- lw and 0.76 μ.g-1 lw for sum PBDEs in harbour seals and harbour porpoises respectively) and were highly dependent of age group and gender. For both species, the highest PCB concentrations were observed in adult males as the result of accumulation for years and years, while the highest PBDE concentrations were measured in juveniles probably due to better developed metabolic capacities for these congeners with age in adults. Results for PCBs were higher than observations in harbour seals and porpoises from other areas, while results for PBDEs were comparable indicating that the North Sea is a highly contaminated area. Relative PCB and PBDE profiles were constructed to compare metabolic capacities between harbour seals and porpoises. A higher contribution of lower chlorinated and nonpersistent congeners, such as CB 52, CB 95, CB 101, CB 118 and CB 149 indicated that harbour porpoises are unable to metabolize these compounds. Similar to PCBs, higher contributions of other PBDEs than BDE 47 were observed in harbour porpoises, suggesting that this species has difficulties to metabolize these congeners. In contrast, harbour seals showed a higher ability to metabolize PCBs and PBDEs

Synthesis and structural characterization of 2-D layered copper(II) styrylphosphonate coordination polymers

We report the synthesis, physicochemical characterization, and crystal structure of Cu-SP (SP = styrylphosphonic acid, H2O3PCH=CH2(C6H5)), the first reported example of a metal derivative of SP. The starting SP acid was fully characterized by X-ray single-crystal diffractometry, elemental analysis (C and H), 31P-NMR, 13C-NMR, 1H-NMR, HPLC, UV–vis, MS, TG, and FT-IR spectroscopy. The copper(II) derivative was synthesized and characterized by DTA-TG and FT-IR, and also its structure was determined from powder data. The crystal structure was refined by the Rietveld method. The crystal structure of Cu-SP shows a layered 2-D architecture, where the organic moieties are pointed toward the interlamellar space. The inorganic layers are composed of Cu2+ dimers, where the coordination geometry of Cu2+ can be described as distorted trigonal bipyramid. The three coplanar oxygens (O2, O3, and O3) have bond distances of 2.165(9), 1.982(9), and 2.103(11) Å, respectively. The bond lengths for the apical oxygens (O1 and O2) are 1.908(13) and 1.996(11) Å, respectively.Proyecto nacional MAT2010-1517

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.</p

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities 1,2 . This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity 3�6 . Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55 of the global rise in mean BMI from 1985 to 2017�and more than 80 in some low- and middle-income regions�was due to increases in BMI in rural areas. This large contribution stems from the fact that, with the exception of women in sub-Saharan Africa, BMI is increasing at the same rate or faster in rural areas than in cities in low- and middle-income regions. These trends have in turn resulted in a closing�and in some countries reversal�of the gap in BMI between urban and rural areas in low- and middle-income countries, especially for women. In high-income and industrialized countries, we noted a persistently higher rural BMI, especially for women. There is an urgent need for an integrated approach to rural nutrition that enhances financial and physical access to healthy foods, to avoid replacing the rural undernutrition disadvantage in poor countries with a more general malnutrition disadvantage that entails excessive consumption of low-quality calories. © 2019, The Author(s)

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol�which is a marker of cardiovascular risk�changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95 credible interval 3.7 million�4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world. © 2020, The Author(s), under exclusive licence to Springer Nature Limited

Levels and profiles of PCBs and PBDEs in harbour seal and harbour porpoise from the southern North Sea

Harbour porpoises (Phocoena phocoena) and harbour seals (Phoca vitulina), two representative top-predator species for the North Sea ecosystem, are good indicators of coastal pollution. Concentrations of sum PCBs were 1-2 orders of magnitude higher than concentrations of sum PBDEs and covered a large range of concentrations (up to 210 μg/g lw and 5.9 μg/g lw for sum PCBs and sum PBDEs). A higher contribution of lower chlorinated congeners and non-persistent congeners, such as CB 52, CB 95, CB 101, CB 118 and CB 149 indicated that harbour porpoises are unable to metabolize these congeners. Similar to PCBs, a higher contribution of other PBDE congeners than BDE 47 was observed in harbour porpoises, suggesting that porpoises have more difficulties to metabolize these congeners. This is also supported by the higher concentrations of sum PBDEs in porpoises. In contrast, harbour seals show a higher ability to metabolize (non-persistent) PCBs

Brominated flame retardants and polychlorinated biphenyls in fish from the river Scheldt, Belgium

Levels of polybrominated diphenyl ethers (PBDEs), hexabromocyclododecanes (HBCDs), and polychlorinated biphenyls (PCBs) were measured in several fish species originating from the river Scheldt (Belgium). Five sampling locations were chosen in a highly industrialized area along the river, while two ponds in the vicinity of the river served as reference sites. The present study is a follow-up of a survey performed in 2000 which reported extremely high levels of PBDEs and HBCDs in eel (Anguilla anguilla) collected from the same region (Oudenaarde, Flanders). The sum of tri- to hepta-BDE congeners (2270 ± 2260 ng/g lipid weight (lw), range 660–11 500 ng/g lw) and total HBCDs (4500 ± 3000 ng/g lw, range 390–12 100 ng/g lw) were one order of magnitude higher than levels usually reported from freshwater systems, indicating the presence of point sources. In most samples, levels of total HBCDs were higher than those of PBDEs, probably due to the high density of factories using HBCD as an additive brominated flame retardant (BFR). The high values of HBCDs were confirmed by both gas- and liquid-chromatography–mass spectrometry. Although BFR levels were between the highest ever reported in freshwater ecosystems, PCBs could be detected at even higher concentrations (16 000 ± 14 300 ng/g lw, range 3900–66 600 ng/g lw), being among the highest levels recorded in Belgium. The inter-sampling site variation of PBDEs, HBCDs and PCBs was comparable. All locations presented similar PBDE congener profiles, with BDE 47 being the dominant congener, followed by BDE 100, BDE 99 and BDE 49, probably originating from the former use of the penta-BDE technical mixture. In order to estimate the impact of these point sources on human exposure, we further focussed on eels which showed a considerable decrease in the PBDE and HBCD levels between 2000 and 2006. Due to the wide span in concentrations between the different sampling locations, a variable contribution to the total human exposure through local eel consumption was estimated. The calculated daily intake ranged from 3 ng to 330 ng PBDEs/day for normal eel consumers, but was as high as 9800 ng PBDEs/day for anglers, which may be considered at risk

A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol

Contains fulltext : 232577.pdf (Publisher’s version ) (Open Access)INTRODUCTION: Systemic sclerosis (SSc) is a chronic, autoimmune connective tissue disease associated with high morbidity and mortality, especially in diffuse cutaneous SSc (dcSSc). Currently, there are several treatments available in early dcSSc that aim to change the disease course, including immunosuppressive agents and autologous haematopoietic stem cell transplantation (HSCT). HSCT has been adopted in international guidelines and is offered in current clinical care. However, optimal timing and patient selection for HSCT are still unclear. In particular, it is unclear whether HSCT should be positioned as upfront therapy or rescue treatment for patients refractory to immunosuppressive therapy. We hypothesise that upfront HSCT is superior and results in lower toxicity and lower long-term medical costs. Therefore, we propose this randomised trial aiming to determine the optimal treatment strategy for early dcSSc by comparing two strategies used in standard care: (1) upfront autologous HSCT versus (2) immunosuppressive therapy (intravenous cyclophosphamide pulse therapy followed by mycophenolate mofetil) with rescue HSCT in case of treatment failure. METHODS AND ANALYSIS: The UPSIDE (UPfront autologous hematopoietic Stem cell transplantation vs Immunosuppressive medication in early DiffusE cutaneous systemic sclerosis) study is a multicentre, randomised, open-label, controlled trial. In total, 120 patients with early dcSSc will be randomised. The primary outcome is event-free survival at 2 years after randomisation. Secondary outcomes include serious adverse events, functional status and health-related quality of life. We will also evaluate changes in nailfold capillaroscopy pattern, pulmonary function, cardiac MR and high-resolution CT of the chest. Follow-up visits will be scheduled 3-monthly for 2 years and annually in the following 3 years. ETHICS AND DISSEMINATION: The study was approved by the Dutch Central Committee on Research Concerning Human Subjects (NL72607.041.20). The results will be disseminated through patient associations and conventional scientific channels. TRIAL REGISTRATION NUMBERS: NCT04464434; NL 8720